AbbVie said on Monday its experimental drug to treat Parkinson's disease met the main goal in a late-stage study.
The drug, tavapadon, helped significantly improve motor functions, including eating and walking, the company said.
The majority of side-effects reported were mild to moderate in severity, it said.
AbbVie plans to submit a marketing application to the U.S. Food & Drug Administration next year.